Oncomine™ Pan-Cancer Cell-Free Assay
-
Targeted plasma-based panel for the detection of actionable driver and resistance mutations with a low limit of detection down to 0.1%.
-
52 genes, 272 amplicons, >900 hotspots and indels, fusions and copy number variations.
-
Preferred 2x10 mL tubes of whole blood
-
Three-day workflow.